Gene Expression in Hyperparathyroidism
Gene Expression in Hyperparathyroidism: Identifying Molecular Differences in MEN1 Patients Versus Young MEN1 Negative Patients
Sponsor: M.D. Anderson Cancer Center
Terminated
At the request of the Principal Investigator
Listed as NCT03044600, this observational or N/A phase trial focuses on Hyperparathyroidism and Parathyroid Disease and remains terminated or withdrawn. Sponsored by M.D. Anderson Cancer Center, it has been updated 13 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
▶ Show 8 earlier versions
-
Jun 2019 — Nov 2020 [monthly]
Terminated
Status: Recruiting → Terminated
-
Feb 2019 — Jun 2019 [monthly]
Recruiting
Status: Completed → Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Completed NA
Status: Recruiting → Completed
-
Aug 2017 — Mar 2018 [monthly]
Recruiting NA
-
Feb 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .